Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights
Tango Therapeutics (NASDAQ: TNGX) reported Q2 2024 financial results and business highlights. Key points include:
1. Ongoing dose expansion in TNG908 and TNG462 phase 1/2 clinical trials, with a comprehensive PRMT5 program update expected in 2H 2024.
2. TNG260 phase 1/2 clinical trial patient enrollment continues.
3. Strong cash position of $322.1 million as of June 30, 2024, with runway into 2027.
4. Q2 2024 financial results: Collaboration revenue $7.8 million, license revenue $12.1 million, R&D expenses $38.7 million, G&A expenses $10.8 million, net loss $25.6 million ($0.24 per share).
5. Gilead licensed a drug discovery program for a $12.0 million fee in June.
Tango Therapeutics (NASDAQ: TNGX) ha riportato i risultati finanziari e i principali sviluppi aziendali del secondo trimestre del 2024. I punti chiave includono:
1. Espansione della dose in corso negli studi clinici di fase 1/2 per TNG908 e TNG462, con un aggiornamento completo del programma PRMT5 previsto per la seconda metà del 2024.
2. Continua l'arruolamento dei pazienti nello studio clinico di fase 1/2 per TNG260.
3. Posizione di cassa solida di 322,1 milioni di dollari al 30 giugno 2024, con proiezioni fino al 2027.
4. Risultati finanziari del Q2 2024: ricavi da collaborazioni 7,8 milioni di dollari, ricavi da licenze 12,1 milioni di dollari, spese per R&S 38,7 milioni di dollari, spese generali e amministrative 10,8 milioni di dollari, perdita netta 25,6 milioni di dollari (0,24 dollari per azione).
5. Gilead ha licenziato un programma di scoperta di farmaci per una quota di 12,0 milioni di dollari a giugno.
Tango Therapeutics (NASDAQ: TNGX) reportó los resultados financieros y los principales aspectos del negocio del segundo trimestre de 2024. Los puntos clave incluyen:
1. Expansión de dosis en curso en los ensayos clínicos de fase 1/2 para TNG908 y TNG462, con una actualización completa del programa PRMT5 prevista para la segunda mitad de 2024.
2. Continúa la inscripción de pacientes en el ensayo clínico de fase 1/2 para TNG260.
3. Fuerte posición de efectivo de 322,1 millones de dólares al 30 de junio de 2024, con proyección hasta 2027.
4. Resultados financieros del Q2 2024: ingresos por colaboración 7,8 millones de dólares, ingresos por licencias 12,1 millones de dólares, gastos de I+D 38,7 millones de dólares, gastos generales y administrativos 10,8 millones de dólares, pérdida neta 25,6 millones de dólares (0,24 dólares por acción).
5. Gilead licenció un programa de descubrimiento de medicamentos por una tarifa de 12,0 millones de dólares en junio.
탱고 테라퓨틱스(Tango Therapeutics, NASDAQ: TNGX)는 2024년 2분기 재무 결과와 비즈니스 주요 내용을 보고했습니다. 주요 내용은 다음과 같습니다:
1. TNG908 및 TNG462 1/2상 임상 시험에서 진행 중인 용량 확장, 2024년 하반기에 PRMT5 프로그램에 대한 포괄적인 업데이트가 예정되어 있습니다.
2. TNG260 1/2상 임상 시험에 대한 환자 등록이 계속 진행되고 있습니다.
3. 2024년 6월 30일 기준 3억 2,210만 달러의 강력한 현금 위치를 보유하고 있으며, 2027년까지의 재정적 여유가 있습니다.
4. 2024년 2분기 재무 결과: 협력 수익 780만 달러, 라이센스 수익 1,210만 달러, 연구개발 비용 3,870만 달러, 일반 관리비 1,080만 달러, 순손실 2,560만 달러(주당 0.24 달러).
5. Gilead는 6월에 1,200만 달러의 요금으로 약물 발견 프로그램을 라이센스했습니다.
Tango Therapeutics (NASDAQ: TNGX) a rapporté les résultats financiers et les faits saillants de son activité pour le deuxième trimestre 2024. Les points clés incluent :
1. Expansion de dose en cours dans les essais cliniques de phase 1/2 pour TNG908 et TNG462, avec une mise à jour complète du programme PRMT5 prévue pour la seconde moitié de 2024.
2. L'inscription des patients dans l'essai clinique de phase 1/2 pour TNG260 se poursuit.
3. Position de trésorerie solide de 322,1 millions de dollars au 30 juin 2024, avec une visibilité jusqu'en 2027.
4. Résultats financiers du T2 2024 : revenus de collaboration de 7,8 millions de dollars, revenus de licences de 12,1 millions de dollars, dépenses en R&D de 38,7 millions de dollars, dépenses générales de 10,8 millions de dollars, perte nette de 25,6 millions de dollars (0,24 dollar par action).
5. Gilead a licencié un programme de découverte de médicaments pour des frais de 12,0 millions de dollars en juin.
Tango Therapeutics (NASDAQ: TNGX) hat die finanziellen Ergebnisse und wichtigen Geschäftszusammenfassungen für das zweite Quartal 2024 veröffentlicht. Die wichtigsten Punkte sind:
1. Fortlaufende Dosissteigerung in den klinischen Studien der Phase 1/2 für TNG908 und TNG462, mit einem umfassenden Update des PRMT5-Programms, das für die zweite Jahreshälfte 2024 erwartet wird.
2. Die Patientenaufnahme in der klinischen Studie der Phase 1/2 für TNG260 geht weiter.
3. Starke Liquiditätsposition von 322,1 Millionen Dollar zum 30. Juni 2024, mit einer finanziellen Planungsperiode bis 2027.
4. Finanzielle Ergebnisse für das Q2 2024: Zusammenarbeitseinnahmen 7,8 Millionen Dollar, Lizenzeinnahmen 12,1 Millionen Dollar, Forschungs- und Entwicklungskosten 38,7 Millionen Dollar, allgemeine Verwaltungskosten 10,8 Millionen Dollar, Nettoverlust 25,6 Millionen Dollar (0,24 Dollar pro Aktie).
5. Gilead Lizenzierte ein Arzneimittelentdeckungsprogramm für eine Gebühr von 12,0 Millionen Dollar im Juni.
- Strong cash position of $322.1 million with runway into 2027
- Gilead licensed a drug discovery program for $12.0 million
- License revenue increased to $12.1 million in Q2 2024 from $5.0 million in Q2 2023
- Ongoing progress in multiple clinical trials (TNG908, TNG462, TNG260)
- Net loss increased to $25.6 million in Q2 2024 from $20.7 million in Q2 2023
- R&D expenses increased to $38.7 million in Q2 2024 from $28.7 million in Q2 2023
- Collaboration revenue decreased to $7.8 million in Q2 2024 from $9.6 million in Q2 2023
Insights
Tango Therapeutics' Q2 2024 results reveal a mixed financial picture. While the company maintains a strong cash position of
However, the
Tango's pipeline progress is encouraging, particularly in the PRMT5 inhibitor space. The ongoing dose expansion trials for TNG908 and TNG462 target MTAP-deleted solid tumors, a significant market affecting
The advancement of TNG260, targeting STK11 mutations, opens up another substantial market across various cancer types. However, the lack of specific efficacy data in this update is notable. The promised comprehensive clinical data update in 2H 2024 will be crucial for assessing the true potential of these therapies and Tango's competitive position in the precision oncology space.
Tango's focus on precision medicine for cancer, particularly its PRMT5 inhibitors and CoREST complex inhibitor, positions it in a high-growth market. The company's strategy of targeting specific genetic mutations (MTAP deletions, STK11 mutations) aligns with the trend towards personalized cancer treatments, which is gaining traction in the oncology field.
The collaboration with Gilead is a significant vote of confidence from a major player in the industry. However, investors should note that Tango is still in early clinical stages and success is far from guaranteed. The upcoming comprehensive clinical data update in 2H 2024 will be a critical inflection point for the company's valuation and future prospects. Until then, the stock may experience volatility based on market sentiment towards early-stage biotech companies.
– Dose expansion ongoing in TNG908 and TNG462 phase 1/2 clinical trials; comprehensive clinical data update for the PRMT5 program expected in 2H 2024 –
– Patient enrollment is ongoing in TNG260 phase 1/2 clinical trial –
– Strong cash position of
“In the second quarter, we continued to advance the dose expansion portions of the TNG908 and TNG462 phase 1/2 clinical trials. We are progressing these molecules with the intent of remaining a leader in developing PRMT5 inhibitors for multiple cancers. We look forward to sharing a comprehensive clinical data update for the PRMT5 program later this year,” said Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics. “In addition, we continue to advance TNG260 for cancers with STK11 loss-of-function mutations and patient enrollment is ongoing in the phase 1/2 clinical trial.”
Recent Business Highlights
Pipeline Update
TNG908, a blood-brain barrier penetrant, MTA-cooperative PRMT5 inhibitor
- Enrollment in the dose expansion portion of the TNG908 phase 1/2 clinical trial is ongoing. Expansion cohorts are being enrolled in MTAP-deleted solid tumors in glioblastoma (GBM), non-small cell lung and pancreatic cancers at 600 mg BID.
-
MTAP deletions occur in approximately
10% -15% of all human cancers, including40% of GBM.
TNG462, a potentially best-in-class MTA-cooperative PRMT5 inhibitor
- The dose expansion portion of the TNG462 phase 1/2 clinical trial is ongoing. Two doses are being evaluated (200 mg QD and 300 mg QD) in non-small cell lung and pancreatic cancer, as well as a histology-agnostic cohort enriched for cholangiocarcinoma, mesothelioma, sarcoma and bladder cancers.
TNG260, a first-in-class, highly selective CoREST complex inhibitor
- The TNG260 phase 1/2 clinical trial is ongoing, evaluating the safety, pharmacokinetics, pharmacodynamics and efficacy of TNG260 in combination with pembrolizumab in patients with locally advanced or metastatic solid tumors with an STK11 loss-of-function mutation. To date, safety, tolerability and pharmacokinetic profiles are favorable.
-
STK11 mutations occur in approximately
15% of non-small cell lung,15% of cervical,10% of carcinoma of unknown primary,5% of breast and3% of pancreatic cancers.
Business Highlights
Gilead strategic collaboration
-
In June, Gilead licensed a drug discovery program for a
license fee.$12.0 million
Upcoming Milestones
- A comprehensive update of the PRMT5 program, including clinical data from the ongoing phase 1/2 clinical trials of TNG908 and TNG462, is expected in 2H 2024.
Financial Results
As of June 30, 2024, the Company held
Collaboration revenue was
License revenue was
Research and development expenses were
General and administrative expenses were
Net loss for the three months ended June 30, 2024 was
About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. For more information, please visit www.tangotx.com.
Forward-Looking Statements
Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events, Tango’s future operating performance and goals, the anticipated benefits of therapies and combination therapies (that include a Tango pipeline product), as well as the expectations, beliefs and development objectives for Tango’s product pipeline and clinical trials. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “goal”, “estimate”, “anticipate”, “believe”, “predict”, “designed,” “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. For example, implicit or explicit statements concerning the following include or constitute forward-looking statements: the Company is progressing its molecules with the intent of remaining a leader in developing PRMT5 inhibitors for multiple cancers; the Company expects cash runway into 2027 and this cash runway is expected to fund all clinical programs through proof-of-concept; the Company is enrolling patients in the dose expansion portion of the TNG908 and TNG462 phase 1/2 clinical trials; the Company expects to share a comprehensive clinical data update on our PRMT5 program later this year; the Company continues to advance TNG260 for cancers with STK11 loss-of-function mutations, with patient enrollment ongoing in the phase 1/2 clinical trial; Tango is committed to discovering and delivering the next generation of precision cancer medicines; and the expected timing of: (i) development candidate declaration for certain targets; (ii) initiating IND-enabling studies; (iii) filing INDs; (iv) clinical trial initiation, dose escalation and dose expansion and (v) disclosing initial, interim, additional and final clinical trial results; and the expected benefits of the Company's development candidates and other product candidates. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Tango and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: benefits of product candidates seen in preclinical tests and analyses may not be evident when tested in later preclinical studies or in clinical trials or when used in broader patient populations (if approved for commercial sale); Tango has limited experience conducting clinical trials (and will rely on a third party to operate its clinical trials) and may not be able to commence the clinical trial (including opening clinical trial sites, dosing the first patient, and continued enrollment and dosing of an adequate number of clinical trial participants) when expected, may not be able to continue dosing, initiate dose escalation and/or dose expansion on anticipated timelines, and may not generate results (including final, initial or additional safety, efficacy data and proof-of-mechanism and proof-of-concept) in the anticipated timeframe (or at all); Tango’s pipeline products may not be safe and/or effective in humans; Tango has a limited operating history and has not generated any revenue to date from product sales, and may never become profitable; other companies may be able to identify and develop product candidates more quickly than the Company and commercially introduce the product prior to the Company; the Company’s proprietary discovery platform is novel and may not identify any synthetic lethal targets for future development; the Company may not be able to identify development candidates on the schedule it anticipates due to technical, financial or other reasons; the Company may not be able to file INDs for development candidates on time, or at all, due to technical or financial reasons or otherwise; the Company may utilize cash resources more quickly than anticipated; Tango will need to raise capital in the future and if we are unable to raise capital when needed or on attractive terms, we would be forced to delay, scale back or discontinue some of our development programs or future commercialization efforts (which may delay filing of INDs, dosing patients, initiation of dose expansion, reporting clinical trial results and filing new drug applications); Tango’s approach to the discovery and development of product candidates is novel and unproven, which makes it difficult to predict the time, cost of development, and likelihood of successfully developing any products; the Company may be unable to advance our preclinical development programs into and through the clinic for safety or efficacy reasons or commercialize our product candidates or we may experience significant delays in doing so as a result of factors beyond Tango’s control; the Company may not be able to realize the benefits of orphan drug or Fast Track designation (and such designations may not advance any anticipated approval timelines); Tango may not identify or discover additional product candidates or may expend limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success; the Company’s product candidates may cause adverse or other undesirable side effects (or may not show requisite efficacy) that could, among other things, delay or prevent regulatory approval; our dependence on one or a limited number third parties for conducting clinical trials and producing drug substance and drug product (including drug substance, which is currently sole sourced); government regulation may negatively impact the Company’s business, including the potential approval of the BIOSECURE Act; and our ability to obtain and maintain patent and other intellectual property protection for our technology and product candidates or the scope of intellectual property protection obtained is not sufficiently broad. Additional information concerning risks, uncertainties and assumptions can be found in Tango’s filings with the Securities and Exchange Commission (SEC), including the risk factors referenced in Tango’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as supplemented and/or modified by its most recent Quarterly Report on Form 10-Q. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Tango specifically disclaims any duty to update these forward-looking statements.
Consolidated Statements of Operations |
||||||||||||||||
(In thousands, except share and per share data) |
||||||||||||||||
|
|
Three Months Ended
|
|
Six Months Ended
|
||||||||||||
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
Collaboration revenue |
|
$ |
7,775 |
|
|
$ |
9,598 |
|
|
$ |
14,246 |
|
|
$ |
15,364 |
|
License revenue |
|
|
12,100 |
|
|
|
5,000 |
|
|
|
12,100 |
|
|
|
5,000 |
|
Total revenue |
|
|
19,875 |
|
|
|
14,598 |
|
|
|
26,346 |
|
|
|
20,364 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
||||||||
Research and development |
|
|
38,654 |
|
|
|
28,671 |
|
|
|
76,719 |
|
|
|
56,710 |
|
General and administrative |
|
|
10,773 |
|
|
|
9,174 |
|
|
|
21,434 |
|
|
|
17,188 |
|
Total operating expenses |
|
|
49,427 |
|
|
|
37,845 |
|
|
|
98,153 |
|
|
|
73,898 |
|
Loss from operations |
|
|
(29,552 |
) |
|
|
(23,247 |
) |
|
|
(71,807 |
) |
|
|
(53,534 |
) |
Other income, net |
|
|
4,066 |
|
|
|
2,601 |
|
|
|
8,447 |
|
|
|
4,880 |
|
Loss before income taxes |
|
|
(25,486 |
) |
|
|
(20,646 |
) |
|
|
(63,360 |
) |
|
|
(48,654 |
) |
Provision for income taxes |
|
|
(65 |
) |
|
|
(64 |
) |
|
|
(105 |
) |
|
|
(64 |
) |
Net loss |
|
$ |
(25,551 |
) |
|
$ |
(20,710 |
) |
|
$ |
(63,465 |
) |
|
$ |
(48,718 |
) |
|
|
|
|
|
|
|
|
|
||||||||
Net loss per common share – basic and diluted |
|
$ |
(0.24 |
) |
|
$ |
(0.23 |
) |
|
$ |
(0.58 |
) |
|
$ |
(0.55 |
) |
Weighted average number of common shares outstanding – basic and diluted |
|
|
108,314,279 |
|
|
|
88,354,590 |
|
|
|
108,692,822 |
|
|
|
88,281,368 |
|
Consolidated Balance Sheets |
||||||||
(In thousands) |
||||||||
|
|
June 30,
|
|
|
December 31,
|
|
||
Assets |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
51,566 |
|
|
$ |
66,385 |
|
Marketable securities |
|
|
270,545 |
|
|
|
270,500 |
|
Restricted cash |
|
|
— |
|
|
|
856 |
|
Prepaid expenses and other current assets |
|
|
6,299 |
|
|
|
8,797 |
|
Total current assets |
|
|
328,410 |
|
|
|
346,538 |
|
Property and equipment, net |
|
|
9,095 |
|
|
|
9,908 |
|
Operating lease right-of-use assets |
|
|
41,371 |
|
|
|
43,508 |
|
Restricted cash, net of current portion |
|
|
2,567 |
|
|
|
2,567 |
|
Other assets |
|
|
10 |
|
|
|
46 |
|
Total assets |
|
$ |
381,453 |
|
|
$ |
402,567 |
|
Liabilities and Stockholders' Equity |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
1,062 |
|
|
$ |
2,785 |
|
Accrued expenses and other current liabilities |
|
|
16,774 |
|
|
|
15,401 |
|
Operating lease liabilities |
|
|
2,364 |
|
|
|
2,082 |
|
Deferred revenue |
|
|
23,668 |
|
|
|
25,670 |
|
Total current liabilities |
|
|
43,868 |
|
|
|
45,938 |
|
Operating lease liabilities, net of current portion |
|
|
35,473 |
|
|
|
36,838 |
|
Deferred revenue, net of current portion |
|
|
54,439 |
|
|
|
66,683 |
|
Total liabilities |
|
|
133,780 |
|
|
|
149,459 |
|
Total stockholders’ equity |
|
|
247,673 |
|
|
|
253,108 |
|
Total liabilities and stockholders’ equity |
|
$ |
381,453 |
|
|
$ |
402,567 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20240807035741/en/
Investor:
Sam Martin/Andrew Vulis
Argot Partners
tango@argotpartners.com
Media:
Amanda Brown Galgay
SVP, Corporate Communications, Tango Therapeutics
media@tangotx.com
Source: Tango Therapeutics, Inc.
FAQ
What were Tango Therapeutics' (TNGX) key financial results for Q2 2024?
What is the cash position of Tango Therapeutics (TNGX) as of June 30, 2024?
What clinical trials is Tango Therapeutics (TNGX) currently conducting?